AOD-9604: Complete Research Guide

AOD-9604 (Advanced Obesity Drug-9604) is a synthetic peptide fragment corresponding to the C-terminal portion of human growth hormone (hGH), specifically amino acids 177-191, with the addition of a tyrosine residue at the N-terminus. It was developed at Monash University in Melbourne, Australia, by Professor Frank Ng and colleagues, who identified that the fat-reducing activity of growth hormone could be isolated to this specific region of the molecule.

The premise behind AOD-9604 is compelling: full-length growth hormone has potent lipolytic (fat-burning) effects, but its clinical use for weight management is limited by serious side effects, including insulin resistance, carpal tunnel syndrome, fluid retention, and the promotion of cell growth that could theoretically increase cancer risk. By isolating the lipolytic region and separating it from the growth-promoting and IGF-1-stimulating regions of the molecule, researchers aimed to create a compound with the fat-loss benefits of GH without its adverse effects.

AOD-9604 underwent several clinical trials for obesity treatment from the early 2000s through the 2010s. While early-phase results were promising, the compound ultimately did not achieve regulatory approval after a large Phase IIb/III trial failed to demonstrate statistically significant weight loss compared to placebo. Despite this clinical setback, AOD-9604 has received regulatory approval from the TGA in Australia as a complementary medicine ingredient (for food-type supplements) and continues to generate research interest.

AOD-9604 is a 16-amino acid peptide with a molecular weight of approximately 1,817 Da. Its sequence is Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe, incorporating a disulphide bond between the two cysteine residues. The tyrosine residue at position 1 is an addition not present in the native hGH 177-191 sequence, included to facilitate biological activity.

The relationship between AOD-9604 and human growth hormone is important to understand. Full-length hGH is a 191-amino acid protein produced by the anterior pituitary gland. Research in the 1990s identified that the C-terminal region (roughly amino acids 177-191) was responsible for a significant portion of GH's effects on fat metabolism. This discovery led to the development of AOD-9604 as a standalone therapeutic candidate.

Critically, AOD-9604 does not bind to the growth hormone receptor (GHR) and does not stimulate the production of insulin-like growth factor 1 (IGF-1). This means it lacks the growth-promoting, anabolic, and diabetogenic properties of full GH. It does not cause cells to proliferate, does not promote insulin resistance, and does not carry the theoretical cancer-promotion risk associated with elevated IGF-1 levels.

AOD-9604 is typically supplied as a lyophilized powder for reconstitution. In research settings, it is administered via subcutaneous injection or, in some studies, orally. The oral bioavailability of AOD-9604 has been explored in clinical trials, with oral capsule formulations used in the Phase IIb/III study.

AOD-9604's mechanism of action centres on fat metabolism, specifically through the regulation of lipolysis and lipogenesis in adipose tissue.

Beta-3 Adrenergic Receptor Pathway: AOD-9604 is believed to mimic the lipolytic action of the C-terminal fragment of GH by stimulating lipolysis through the beta-3 adrenergic receptor (β3-AR) pathway. This receptor is predominantly found on adipocytes (fat cells) and, when activated, triggers the breakdown of stored triglycerides into free fatty acids and glycerol.

Stimulation of Lipolysis: The peptide enhances the release of stored fat from adipose tissue by activating hormone-sensitive lipase (HSL). This enzyme is the primary catalyst for the hydrolysis of triglycerides in fat cells. AOD-9604 appears to upregulate HSL activity through a signalling cascade involving cAMP and protein kinase A.

Inhibition of Lipogenesis: In addition to breaking down existing fat, AOD-9604 has been shown to inhibit de novo lipogenesis — the process by which the body synthesises new fatty acids from non-fat precursors like glucose. By simultaneously promoting fat breakdown and preventing new fat formation, AOD-9604 addresses both sides of the fat balance equation.

No GH Receptor Binding: AOD-9604 does not bind to the GH receptor and therefore does not activate the JAK2/STAT5 signalling pathway responsible for GH's growth-promoting and IGF-1-stimulating effects. This is the basis of its safety advantage over full-length GH.

Potential Cartilage Effects: Interestingly, more recent research has explored AOD-9604's potential effects on cartilage and joint health, independent of its fat metabolism activity. Some studies suggest it may promote proteoglycan and collagen synthesis in chondrocytes, leading to interest in osteoarthritis applications.

AOD-9604 has been investigated primarily for metabolic applications, with emerging research in musculoskeletal health.

• Obesity and Weight Management: The primary research application. Phase I and Phase II clinical trials demonstrated that AOD-9604 could induce weight loss in obese subjects. A 12-week Phase II study showed statistically significant weight loss compared to placebo at certain dose levels (1 mg/day oral), with subjects losing an average of 2.6 kg. However, the larger Phase IIb/III trial did not meet its primary endpoint of statistically significant weight loss, effectively halting its pharmaceutical development for this indication.

• Fat Metabolism (Preclinical): Animal studies have been more consistently positive. In obese mice and rats, AOD-9604 significantly reduced body fat without affecting lean mass, food intake, or IGF-1 levels. In Zucker (obese) rats, it reduced body fat by approximately 50% over a 19-day treatment period.

• Osteoarthritis and Joint Health: AOD-9604 has shown promise in promoting cartilage repair and reducing joint inflammation. Intra-articular injection studies have demonstrated stimulation of proteoglycan synthesis by chondrocytes. The Australian company that owns AOD-9604 rights has pursued clinical development for osteoarthritis under the designation "i-body."

• Bone Health: Preliminary data suggest AOD-9604 may support bone health by promoting osteoblast activity and inhibiting osteoclast-mediated bone resorption.

• Cardiovascular Risk Factors: Research has explored whether AOD-9604's fat-reducing effects translate to improvements in cardiovascular risk markers, including lipid profiles and inflammatory markers.

Dosage information for AOD-9604 comes from clinical trial data and research protocols.

• Subcutaneous Injection: In research settings, subcutaneous doses commonly range from 250 to 600 mcg per day, administered once daily, typically in the morning on an empty stomach.

• Oral Administration: Clinical trials used oral capsule doses ranging from 0.25 mg to 9 mg per day. The Phase II study that showed positive results used a dose of 1 mg per day orally.

• Intra-articular Injection: For osteoarthritis research, AOD-9604 has been administered via direct injection into the joint. Specific doses in these studies are proprietary but involve single or repeated injections.

• Administration Guidelines:
• - Administer on an empty stomach (fasting state)
• - Wait at least 30 minutes before eating after administration
• - Morning administration is preferred in fat-metabolism studies
• - Fasting administration is important because food intake can interfere with the peptide's metabolic effects

• Cycle Duration: Research protocols typically run for 12 to 24 weeks. The Phase IIb/III clinical trial ran for 24 weeks.

• Reconstitution: For injectable research, AOD-9604 is supplied as lyophilized powder and reconstituted with bacteriostatic water. Store reconstituted solution refrigerated.

It is important to note that the optimal dosing for AOD-9604 remains uncertain, as clinical development was not completed through to regulatory approval for its obesity indication.

AOD-9604 has demonstrated a favourable safety profile in both preclinical and clinical studies.

Clinical Trial Safety Data: Across multiple clinical trials involving over 900 subjects, AOD-9604 was generally well-tolerated. The compound received GRAS (Generally Recognised as Safe) status from the FDA for use as a food ingredient.

Key Safety Advantages Over Growth Hormone: • Does not affect blood glucose levels or insulin sensitivity (no diabetogenic effects) • Does not elevate IGF-1 levels (no growth-promoting or potential cancer-promotion concerns) • Does not cause the fluid retention, joint pain, or carpal tunnel syndrome associated with GH therapy • Does not affect the body's natural GH production or pituitary function

Commonly Reported Side Effects in Clinical Trials: • Headache • Upper respiratory tract infections • Gastrointestinal discomfort (mild) • Injection site reactions (for subcutaneous administration) • These side effects were generally mild and occurred at similar rates in both treatment and placebo groups

Long-term Safety: Animal toxicology studies using doses significantly higher than those used in clinical trials showed no evidence of tumour promotion, organ toxicity, or reproductive toxicity.

Considerations: • As with any peptide affecting fat metabolism, individuals with eating disorders should exercise caution • The long-term safety of chronic AOD-9604 use in humans has not been fully characterised • Pregnant and breastfeeding women should avoid AOD-9604 • Individuals on diabetes medications should consult their healthcare provider, as changes in fat metabolism could theoretically interact with glucose management

AOD-9604 is not approved by Health Canada as a therapeutic drug. Its regulatory status in Canada is as a research chemical, with no authorised indication for human medical use.

Internationally, AOD-9604's regulatory journey has been more eventful:

• Australia: The Therapeutic Goods Administration (TGA) approved AOD-9604 as a Listed Complementary Medicine ingredient in 2019, allowing it to be included in certain food-type supplement products. This approval was based on safety data from clinical trials but does not constitute approval as a pharmaceutical drug.

• United States: The FDA granted GRAS status for AOD-9604 as a food ingredient. However, it is not approved as a drug. The FDA has sent warning letters to companies marketing injectable AOD-9604 products for human use.

In Canada, AOD-9604 can be obtained through research chemical suppliers for legitimate research purposes. It is not available through pharmacies, even compounding pharmacies, as it lacks the prescribing history and regulatory framework that compounds like Sermorelin have.

WADA does not specifically list AOD-9604 on its Prohibited List, and its regulatory classification as a GH fragment (rather than a GH secretagogue) places it in a different category. However, athletes should consult with their sport's anti-doping authority before use.

Canadians should be aware that the quality and purity of AOD-9604 from research chemical suppliers is unregulated. Third-party testing certificates (COA) and HPLC purity reports are essential when sourcing this peptide for research.